GMDA Gamida Cell Ltd.

4.7
-0.05  -1%
Previous Close 4.75
Open 4.75
Price To Book 9.22
Market Cap 120,350,188
Shares 25,606,423
Volume 93,396
Short Ratio
Av. Daily Volume 32,205

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 additional data due 2H 2019.
NAM-NK
Non-Hodgkin lymphoma; Multiple myeloma
Phase 1/2 enrolment of second cohort to begin 1H 2019.
NiCord
Severe aplastic anemia
Phase 3 top-line data due 1H 2020.
NiCord (omidubice)
Acute myeloid leukemia

Latest News

  1. Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
  2. Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares
  3. ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING OF ORDINARY SHARES
  4. Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares
  5. Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel
  6. Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer
  7. Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting
  8. Gamida Cell to Hold Annual Meeting of Stockholders
  9. Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City
  10. Gamida Cell: 1Q Earnings Snapshot
  11. Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update
  12. Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast
  13. Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
  14. Gamida Cell to Present at the 18th Annual Needham Healthcare Conference
  15. Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
  16. Gamida Cell Sees Hammer Chart Pattern: Time to Buy?
  17. Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
  18. Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting
  19. Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
  20. Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells